We used whole exome sequencing (WES) to determine the genetic etiology of a patient with a 4 4
multi-system disorder characterized by a seizure phenotype. WES identified a heterozygous de 4 5 novo missense mutation in the GABRA1 gene (c.875C>T). GABRA1 encodes the alpha subunit 4 6 of the Gamma-Aminobutyric Acid receptor A (GABA A R). The GABA A R is a ligand gated ion 4 7
channel that mediates the fast inhibitory signals of the nervous system and mutations in the 4 8 sub-units that compose the GABA A R have been previously associated with human disease. To 4 9
understand the mechanisms by which GABRA1 regulates brain development, we developed a 5 0 zebrafish model of gabra1 deficiency. gabra1 expression is restricted to the nervous system and 5 1 behavioral analysis of morpholino injected larvae suggests that the knockdown of gabra1 results 5 2 in hypoactivity and defects in the expression of other sub-units of the GABA A R. Expression the 5 3 human GABRA1 protein in morphants partially restored the hypomotility phenotype. In contrast, 5 4
the expression of the c.875C>T variant did not restore these behavioral deficits. Collectively, 5 5
these results represent a functional approach to understand the mechanisms by which loss of 5 6 function alleles cause disease. 5 7 5 8 5 9
INTRODUCTION
In 2013, the Undiagnosed Disease Network (UDN) was founded and includes seven 7 1 clinical sites across the nation, a coordinating center, two DNA sequencing centers, a model 7 2 organism screening center, a metabolomics core, and a central biorepository (Macnamara et al., 7 3 2019). Within the first 4 years of the UDN, the sequencing centers identified 956 genes 7 4 associated with human disease, 375 of them have not previously been associated with disease 7 5 (Wangler et al., 2017) . This is a staggering number, as it suggests that nearly 1/3 of the genes 7 6
identified are of unknown function. These data strongly support the need for in vivo functional 7 7
analysis of gene function. 7 8
Here we describe the identification of a putative disease variant and perform in vivo 7 9 functional analysis of gene function using genetic loss of function. We describe a patient who 8 0
presented with a severe seizure disorder, intellectual disability, cardiac arrhythmia, and non-8 1 verbal speech. We identified a heterozygous de novo missense mutation in the GABRA1 gene 8 2 (c.875C>T), which resulted in a single amino acid substitution in one of the three known 8 3 transmembrane domains (p.Thr292Ile). GABRA1 is located on chromosome 5 and encodes the 8 4 alpha (α) sub-unit of the multi-sub-unit gamma-aminobutyric acid receptor (GABA A R). The 8 5 GABA A R is the primary inhibitory receptor of the central nervous system and the c.875C>T 8 6
variant was previously associated with epileptic phenotypes in the Epi4K consortium (Epi4K 8 7 Consortium et al., 2013) sequencing also confirmed that the variant is de novo (Fig. 1B) and mostly likely the result of a 1 5 0 germline mutation. Amino acid Thr292 is highly conserved evolutionarily between multiple 1 5 1 vertebral species (Fig. 1C Consequently, we developed a protocol using the Zebrabox behavioral unit to monitor swim 1 8 0 speed and total distance swam in larvae injected with anti-sense morpholinos that inhibit either 1 8 1 the translation of gabra1 or mRNA splicing. Embryos were injected at the single cell stage with 1 8 2 randomized control morpholinos (RC), translational targeting morpholinos (tbMO), or mRNA 1 8 3 disrupting morpholinos (sMO) and raised to 5 DPF. Larvae were monitored according to the 1 8 4
protocol described in the MATERIALS AND METHODS for swim speed and total distance swam. 1 8 5
As shown in Figure 3 , the tbMO was associated with a statistically significant (p<0.001) 1 8 6 reduction in total swim speed ( Fig. 3A ) and decreased total distance swam ( Fig. 3B ) consistent 1 8 7
with a hypomotility phenotype. The decrease in speed and distance was observed in both light 1 8 8
and dark conditions at 5 DPF ( Fig. 3C ). Importantly, injection of an equivalent concentration of 1 8 9 sMO induced a hypomotility phenotype ( Fig. S1B ,C; p=0.0263). These results are consistent 1 9 0 with the phenotype present in morphants injected with the translational blocking morpholino. 1 9 1 Importantly, we validated the effects of injection of sMO on mRNA splicing, which demonstrated 1 9 2 a near 50% reduction in wildtype gabra1 (Fig. S1A ). 1 9 3
Next, we sought to restore the hypomotility phenotype in morphants (tbMO) by co-1 9 4
injection of GABRA1 encoding mRNA. Embryos were injected at the single cell stage with RC 1 9 5 morpholinos, tbMO morpholinos, GABRA1 mRNA, or a combination of GABRA1 mRNA with RC 1 9 6 or tbMO morpholinos. Injection of the tbMO caused a statistically significant decrease in the 1 9 7 total distance swam (p= 0.000161) and the overall swim speed (p=0.036384) ( Fig.4A,B ; RC 1 9 8 relative to tbMO). Injection of GABRA1 encoding mRNA had no significant effect on speed or 1 9 9
distance at a concentration of 1000pg/embryo ( Fig. 4A,B ; mRNA and RC+). The co-injection of 2 0 0 the tbMO and GABRA1 encoding mRNA at 1000pg/embryo restored the total distance swam to 2 0 1 normal levels (p= 0.003010689), but was not sufficient to restore the deficits in overall speed to 2 0 2 control levels ( Fig. 4A,B ). Thus, co-injection of 1000pg of GABRA1 encoding mRNA with the 2 0 3 tbMO produced a partial rescue of the observed phenotype. Injection of GABRA1 mRNA at 2 0 4 higher concentrations was accompanied by some degree of toxicity (cardiac edema and death) 2 0 5
and therefore, additional rescue experiments with higher concentrations could not be attempted. 2 0 6 2 0 7
The c.875C>T GABRA1 variant does not restore the hypomotility phenotype in 2 0 8 morphants. 2 0 9
The functional consequences of the c.875C>T variant are currently unknown. Therefore, 2 1 0
we asked whether expression of the c.875C>T variant was sufficient to restore the hypomotility 2 1 1 induced by knockdown of gabra1. Embryos were injected at the single cell stage with RC 2 1 2 morpholinos, tbMO morpholinos, GABRA1 c.875C>T mRNA (SDM), or a combination of 2 1 3 GABRA1 mRNA with tbMO morpholinos. Consistent with previous experiments, injection of the 2 1 4 tbMO morpholino caused a significant reduction (p=0.0153) in the total distance swam relative 2 1 5
to embryos injected with the RC (Fig. 4C) . Interestingly, the co-injection of the mRNA encoding 2 1 6 the c.875C>T (SDM) and the tbMO was unable to restore the total distance traveled to control 2 1 7 levels (Fig. 4C) . Importantly, the injection of the GABRA1 c.875C>T variant (SDM) at 2 1 8 1000pg/embryo had no significant effects on the total distance swam ( Fig. 4C ). 2 1 9
The expression of gabrb2 and gabrg2 are decreased in gabra1 morphants.
0
Previous studies suggest that approximately 60% of all GABA A Rs consist of two α 1, two 2 2 1 β 2, and one γ 2 subunits (Sigel and Steinmann, 2012) . We hypothesized that the knockdown of 2 2 2 gabra1, which encodes the α 1 sub-unit would alter the sub-unit composition of the GABA A R. To  2  2  3 begin to test this, we analyzed the expression of the genes that encode the β 2 and γ 2 sub-units. 2 2 4
As shown in Figure 5A , knockdown of gabra1 caused a decrease in the expression of gabrb2 2 2 5
(β2) and gabrg2 (γ2). We next measured the expression of other alpha sub-units in gabra1 2 2 6 morphants. As shown in Figure 5A , injection of the tbMO was associated with increased 2 2 7 expression of gabra6a and gabra6b, but only gabra6b was statistically significant across 2 2 8 biological triplicates. A similar expression pattern of gabra6a and gabra6b was observed upon 2 2 9
injection of the sMO (Fig. S1D) , with both genes demonstrating a statistically significant 2 3 0 increase in expression. We did not detect a statistical change in the expression of any other α 2 3 1 sub-unit across either the tbMO or the sMO (Figs 5A, S1D).
3 2
We sought to build upon these data by determining whether morphant larvae had an 2 3 3
intact receptor capable of responding to pentylenetetrazol (PTZ), an antagonist of the GABA A R. 2 3 4
Non-injected wildtype embryos treated with 10mM PTZ exhibit short convulsions and a whirlpool 2 3 5 swimming behavior with a 2-fold increase in swim speed (p= 6.74E-06) and an approximate 6-2 3 6
fold increase in total distance swam (p= 2.14E-05) (Fig. 5B,C) . These phenotypes were 2 3 7
consistently observed in larvae injected with RC morpholinos as the RC morpholino had no 2 3 8 affect on larval behavior or their response to PTZ. Interestingly, gabra1 morphants (tbMO) 2 3 9
responded normally to PTZ according to both distance and speed measurements (Fig. 5B,C shown). This can likely be attributed to the fact that our study is performed using a knockdown 2 9 3 of gabra1, which maybe more consistent with the heterozygous phenotypes reported by 2 9 4
Samarut and colleagues at 4 DPF. To address the function of the c.875C>T GABRA1 variant, 2 9 5
we performed restoration experiments in which this variant was co-injected with gabra1 2 9 6 targeting morpholinos. Co-injection of mRNA encoding the c.875C>T variant did not restore the 2 9 7 hypomotility phenotype present in morphants, whereas co-injection of wildtype GABRA1 2 9 8 restored the total distance travels to control levels. These data suggest that the c.875C>T 2 9 9
variant is a loss of function allele, however, future studies characterizing the function of this 3 0 0 variant are warranted. Should this allele be a loss of function allele, morpholino mediated 3 0 1 knockdown is an alternative approach towards understanding the mechanisms by which the 3 0 2 c.875C>T allele causes disease. 3 0 3
We disinhibition (Huang et al., 2001) . The continued response of morphants to PTZ, suggests that 3 0 9
these embryos maintain the ability to produce some form of the GABA A R. Consistent with this 3 1 0 hypothesis, we observed increased expression of gabra6a and gabra6b mRNA, which encode 3 1 1 the two zebrafish The gene expression changes we observe are strongly supported by previous 3 1 8
conclusions in mice with mutations in the Gabra1 gene (Arain et al., 2015; Zhou et al., 2015) . 3 1 9
Recent work in zebrafish has demonstrated that the homozygous nonsense mutation of gabra1, 3 2 0 does not disrupt overall brain structure or the total number of GABAergic cells, but does 3 2 1 influence the brain transcriptome (Samarut et al., 2018) . Collectively, these data raise the 3 2 2 possibility that other alpha sub-units may compensate for the loss of gabra1, ultimately 3 2 3
producing unique compositions of the GABA A R. The function of these receptors is unknown. But 3 2 4
it is conceivable that the production of GABA A R with unique sub-unit composition in incorrect 3 2 5
regions of the brain might underlie the impaired synapse formation observed in zebrafish 3 2 6
harboring germline mutations in the gabra1 gene (Samarut et al., 2018) . 3 2 7
We provide strong evidence that heterozygous de novo mutation of GABRA1 is 3 2 8 associated with a multi-system disorder characterized by severe seizures. We further 3 2 9
characterized the developmental and behavioral defects associated with knockdown of gabra1 3 3 0 in zebrafish. Behaviorally, morphant animals present with hypomotility at 5 DPF measured by 3 3 1 reduced swim speed and total distance traveled. These deficits coincide with significant 3 3 2 changes in the expression of GABA A R sub-units and cannot be restored by the de novo 3 3 3 c.875C>T allele. Although a zebrafish harboring a mutation in the gabra1 gene has recently 3 3 4
been created, detailed behavioral analysis was performed at the juvenile stage (weeks post 3 3 5 fertilization). Here we complement previous studies using a morpholino mediated knockdown 3 3 6 approach, as the homozygous deletion of gabra1 was lethal (Samarut et al., 2018) . Our 3 3 7
behavioral study is the first to our knowledge that comprehensively characterizes the phenotype 3 3 8
of gabra1 deletion during early development (DPF as opposed to weeks post fertilization). We 3 3 9 observed hypomotility consistent with previous studies in zebrafish and our study likely informs 3 4 0 about specific types of mutations, those of which result in loss of function alleles. Importantly, 3 4 1
our restoration experiments with the c.875C>T allele suggest that this allele is in fact a loss of 3 4 2 function allele. They were maintained and bred in groups of two females and two to four males. The collected 3 5 0 zebrafish embryos were kept in egg water consisting of 0.03% Instant Ocean (Aquaneering, 3 5 1
San Diego, CA) in D.I. water at 28°C. 3 5 2 3 5 3 3  5  4 High quality, unamplified, and unfragmented genomic DNA (A260/A280 models. In the dominant model, variants found in any database (dbSNP, 1000 Genomes, EVS, 3 7 1
Whole-Exome Sequencing and Data Analysis
ExAC) were removed from the top candidacy list. In the recessive model, autosomal variants 3 7 2 which had homozygotes found in the databases, such as EVS and ExAC, (or variants on chrX 3 7 3
or chrY with hemizygotes in databases) were deleted from the top candidacy list. 3 7 4 3 7 5
Sanger Sequencing Verification 3 7 6
Sanger sequencing was used to validate the variant described. Briefly, primers were 3 7 7
used to amplify the PCR product (fwd 5'-GCTGTFATAGGGTGGAGGTG-3', rev 3 7 8 5'GCTATCAACGCCATTGTGAA-3') using 1X GoTaq Green (Promega, Madison, WI) with a 3 7 9
final primer concentration of 0.2uM. Reaction parameters for PCR include an initial cycle at 3 8 0 95°C for 10 minutes, followed by 30 cycles of 95°C for 30 seconds, 60°C for 30 second, and 3 8 1 72°C for 1 minute, finishing with extension at 72°C for 5 minutes. Amplified PCR products were 3 8 2 sequenced using the PCR primers as sequencing primers. Variations detected in GABRA1 were 3 8 3 assigned using cDNA accession number NM_000806.5. 3 8 4 3 8 5
Whole mount in situ hybridization and Injections 3 8 6 WISH was performed as previously described (Thisse and Thisse, 2008 TAAGCTGCGCTCTTCTCCTC-3', gabra1 ISH rev 5'-GCAGAGTCCCTTCCTCTGTG-3'). 4 0 4
For morpholino injections, a translational blocking morpholino (tbMO) 4 0 5
(TCTTCCACCCCACATCATTCTCCGA) and a splice site inhibiting morpholino (sMO) 4 0 6 (ACACGCTCTGTTGAAGCAAGAAATT) targeting gabra1 were designed. The efficiency of 4 0 7 knockdown for the sMO was performed with primers flanking the target site (Fwd: 4 0 8 GACAGCCTCCTCGATGGTTA and Rev: GCAGAGTCCCTTCCTCTGTG). Each morpholino 4 0 9
was injected independently at the single cell stage at a concentration of 1.6 ng/embryo. An 4 1 0 equivalent concentration of randomized control morpholinos (25-N) was injected as a control. 4 1 1
Final concentration of morpholino was determined empirically after an injection gradient was 4 1 2 performed to determine optimal survival. For rescue experiments, the human GABRA1 4 1 3 complete open reading frame was purchased from TransOMIC Technologies (Huntsville, AL). 4 1 4
The c.875C>T GABRA1 variant was created from the original vector obtained from TransOMIC 4 1 5
Technologies using the QuikChange II Site-Directed Mutagenesis Kit (Fisher, Waltham, MA) 4 1 6
with forward (TAACAACTGTGCTCATCATGACAACATTGAG) and reverse primers 4 1 7
(GAGTTACAACAGTACGACTCGTGTCAACAAT). In vitro RNA was synthesized using the 4 1 8
mMessage Machine kit (Fisher, Waltham, MA). The synthesized mRNA was injected at the 4 1 9 single cell stage alone or in conjunction with tbMO at the indicated concentrations in the figure 1 6 small and large movements(smldur+lardur)}. Statistical significance was determined according 4 5 3
to a T-test. All experiments were performed in biological triplicate. For PTZ treatment, PTZ 4 5 4 (10mM) was added directly to the 96 well plate following acclimation period. Final concentration 4 5 5
of PTZ was determined from previously published results ( 
